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Eutilia Freire,*,**** Adriana Bruscato,** Rozana Ciconelli***,****
de pacientes com lupus eritematoso sistêmico
(LES).
Métodos:Sessenta e três pacientes com diagnósti-
co de LES foram selecionados no nosso serviço mé-
dico, avaliados em 1999 e revistos em 2005. Nas
duas avaliações nós utilizamos um protocolo para
obter dados sociais, demográficos e clínicos, índi-
ces de atividade e dano e a qualidade de vida atra-
vés do SF-36. Todos os testes estatísticos foram exe-
cutados usando um nível de significância de 5%. 
Resultados:Dos 63 pacientes examinados em 1999,
seis morreram, quatro foram perdidos o contato e
o protocolo precedente foi aplicado outra vez aos
53 pacientes restantes. Os seis pacientes que mor-
reram apresentaram os piores índices de qualida-
de de vida, em todos os aspectos. O factor predic-
tivo observado mais importante foi a baixa pon-
tuação no domínio emocional do componente
mental do SF-36 (p< 0.01).
Conclusão:A qualidade de vida relacionada com a
saúde pode ser usada como possível fator prediti-
vo de mortalidade entre pacientes com LES.
Palavras-chaves: Lupus; Predictor; Qualidade de
Vida Relacionada a Saúde; Sobrevida; SF-36.
Introduction
Systemic lupus erythematosus (SLE) is a chronic
autoimmune disease with a mortality rate 1.5 to 5
times greater than the general population.1 Many
demographic predictors of survival have been iden-
tified in previous studies, such as age at disease on-
set, sex, ethnicity and socioeconomic status.1 Fac-
tors relating to renal disease, central nervous sys-
tem disease, serositis, hemolytic anaemia and
thrombocytopenia have also been identified.1
However, there is some disagreement among pre-
vious studies with regard to ethnicity and socioe-
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Abstract
Objective:To identify social, demographic and cli-
nical characteristics that influence survival of pa-
tients with systemic lupus erythematosus (SLE).
Methods: Sixty-three patients with a diagnosis of
SLE were studied at our medical services in 1999
and then reviewed in 2005. We utilized a protocol
to obtain demographic and clinical traits, activity
and damage indices, and health-related quality of
life via the SF-36. All statistical tests were performed
using a significance level of 5%. 
Results:Out of the 63 patients examined in 1999, six
died, four were lost for the follow-up and the previous
protocol was applied to the remaining 53 patients.
The six patients who died presented the worst recor-
ded health-related quality of life, in all aspects. The
most important observed predictor of death was a
mean lower score in the Role-Emotional Domain of
the mental health component of the SF-36 (p<0.01).
Conclusion: Health-related quality of life may be
used as possible predictive factor of mortality
among patients with SLE.
Keywords:Lupus; Predictor; Health-related Quality
of Life; Survival; SF-36.
Resumo
Objetivo: Identificar as características sociais, de-
mográficas e clínicas que influenciam a sobrevida
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conomic status.2 It is now recognized that a more
comprehensive evaluation of this disease also re-
quires the characterization of parameters that pa-
tients themselves report, such as health-related
quality of life (QOL) as an independent variable.3-7
This topic has been quite well reported in previous
studies on SLE, but this variable has not been used
as a predictor for mortality due to this disease. The
present study was conducted over a five-year pe-
riod and evaluates QOL using the ‘Medical Outco-
mes Survey Short Form 36’ questionnaire (SF-36)
and also sociodemographic and clinical variables,
in an attempt to identify predictors of survival for
this disease.
Patients and Methods
For this observational cohort study, 63 patients
seen at the rheumatology clinic of the university
hospital of the Federal University of Paraíba, in the
State of Paraíba, northeastern Brazil, in 1999 were
included. These patients were diagnosed with SLE,
using the classification criteria recommended by
the American College of Rheumatology (ACR).8
In accordance with the protocol adopted in the
present study, each patient was investigated with
respect to age, duration of disease, ethnicity, gen-
der, income, length of schooling, clinical manifes-
tations, activity, as assessed by the systemic lupus
erythematosus activity index (SLEDAI 2K)9, irrever-
sible damage, as assessed by the Systemic Lupus
International Collaborative Clinics/ACR damage
index (SLICC/ACR-DI)10, and health-related QOL,
as assessed by Brazilian validated version of the 
SF-36.11 
In 2005 these patients were again recruited. Pa-
tients who did not attend our call were invited
through their relatives, by letter or phone call. Their
medical files were also reviewed. Six patients had
died and four had abandoned follow-up. The pa-
tients’ survival was calculated as the period from
the date of baseline evaluation to their death.
Statistical analysis
Pearson’s chi-square method was used to analyze
associations between deaths due to SLE and the so-
ciodemographic variables, ACR criteria, SLEDAI
2K, and SLICC/ACR-DI. The means for deaths due
to SLE and for patients who did not die were com-
pared and analyzed with regard to the SF-36 doma-
ins, using the Student t and Mann-Whitney tests.
All statistical tests were performed using a signifi-
cance level of 5% (p<0.05).
The survival curve was analyzed using the Ka-
plan-Meier method, with a 95% confidence inter-
val, over the time period from June 1999 to Decem-
ber 2005.
Results
The patient assessments carried out in 1999 resul-
ted in a cross-sectional descriptive study of a po-
pulation in northeastern Brazil, and these patients’
demographic and clinic characteristics are presen-
ted in Table I. At the second assessment, in 2005,
four patients were lost for follow-up, because they
had changed residency. Six patients had died, two
from generalized infection after the use of immu-
nossupressors for SLE activity control, two from
renal complications of SLE and two from nervous
system complications of SLE. 
On the survival curve in Figure 1 it can be seen
that 89% of the patients survived for more than 79
months, e.g. 6.5 years, with a mean Kaplan-Meier
survival of 73 months (95% confidence interval
from 69 to 77 months). The mean SLEDAI 2K sco-
re was 2.5 for the 63 patients originally examined,
and ten patients presented very active disease
(SLEDAI 2K > 8) at the first assessment. There was
no difference between deceased and survivors
(p=0.41). Twenty patients presented irreversible
damage, with SLICC/ACR-DI scores ranging from
1 to 5 (mean of 1.5). The damage observed in the-
se 20 patients and the respective numbers of pa-
tients affected were: renal (three), ocular (four),
neurological (five), pulmonary (three), cardiovas-
cular (two), peripheral cardiovascular (three), and
Table I. Means and standard deviations (SD) of 
the demographic characteristics of the 63 patients
with SLE at baseline evaluation
Demographic characteristics Mean (SD)
Age (years) 39.9 (15,0)
Mean income per month 300 (220)
(dollars per family of four people)
Schooling (years) 5.4 (5.2)
Disease duration (years) 6.8 (6.2)
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Mean disease duration among the patients who
died was shorter, but without statistical significan-
ce at the nonparametric tests (Table II). 
With regard to health-related QOL, the mean
scores in the SF-36 domains are shown in Table II.
A low level of QOL was observed for the study po-
pulation at the first assessment and the six patients
who died presented the worst QOL scores, in ge-
neral (Figure 2). They presented significant diffe-
rences regarding scores in Role-emotional
(p<0.01), general health (p=0.05) and Role-physi-
cal (p=0.03) domains and had worse mental-health
summary component scores (p<0.001) in compa-
rison with the survivors (Table II). 
Discussion
In our previous study, we reported that SLE pa-
tients in northeastern Brazil presented lower QOL
than did the general population.12 However, no re-
lationship with patients’ activities or any other cli-
nical aspect of the disease was established in that
study, although there was a significant correlation
with disease duration and chronic damage, which
yielded worse QOL scores.12 In the present study,
the same patients were reevaluated five years later
chronic alopecia and tissue loss in the face (one).
Three of these 20 patients presented damage at
more than one organ system. The patients who
died had renal, neuropsychiatric, pulmonary and
cutaneous damage and yielded higher mean
SLICC/ACR-DI scores than survivors at baseline
measurement (p=0.07). 
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Figure 1. Kaplan-Meier estimated survival curve for 63
patients with SLE.
Table II. Means and standard deviations (SD) of patients' characteristics and p-values from the Student t 
and Mann-Whitney tests at second evaluation.
Mean (SD)
Patients Patients 
All patients who survived who died  Student t test Mann-Whitney
Characteristics n=63 n=53 n=6 p-value p-value
Disease duration 6.8 (6.2) 6.9 (7.0) 4.0 (1.4) 0.01 0.61
SLEDAI 2Ka 2.5 (2.9) 2.6 (3.1) 1.4 (1.9) 0.31 0.41
SLICC/ACR-DIb 1.5 (4) 1.0 (2) 2.5 (2) 0.05 0.07
PFc 59 (27) 59 (28) 60 (20) 0.94 0.91
RPd 60 (38) 64 (36) 29 (42) 0.02 0.03
BPe 61 (25) 63 (24) 50 (32) 0.22 0.26
GHf 59 (21) 60 (21) 45 (13) 0.02 0.05
VIg 61 (23) 62 (24) 49 (19) 0.14 0.10
SFh 67 (27) 69 (27) 50 (18) 0.03 0.06
REi 59 (37) 64 (35) 19 (18) < 0.01 < 0.01
MHj 66 (25) 68 (25) 51 (19) 0.06 0.049
PHSk 41.4 41.9 39.6 0.53 0.48
MHSl 48.4 46.8 35.6 0.001 0.001
aSLEDAI 2K: Systemic Lupus Erythematosus Disease Activity Index, bSLICC/ACR-DI: Damage Index, cPF: Physical function, dRP- Role-physical, eBP: Bodily pain,
fGH: General health, gVI -Vitality, hSF: Social function, iRE: Role-emotional, jMH: Mental health, kPHS: Physical health summary, lMHS: Mental health summary.
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and, for the first time, we were able to show that the
emotional aspects of patients’ QOL are related to
survival at 5 years. This was mainly with regard to
limitations due to emotional aspects of QOL (Role
Emotion domain of SF-36), and there was a signi-
ficant difference between deceased and survivors
(p<0.01). This observation confirms that this para-
meter is an important predictor that should be eva-
luated in cases of this disease, since the survivors
we reexamined did not show any difference be-
tween the assessments in 1999 and 2005.
We acknowledge the fact that this was not ne-
cessarily a representative, significant sample of all
patients with SLE. Nonetheless, the number of pa-
tients involved was representative of the daily at-
tendance at our rheumatology clinic over a one-
-year period. 
The main gain from the present work was the
evaluation of health-related QOL issues among pa-
tients with worse evolution who died. This was
achieved by reevaluating the survivors, who gene-
rally presented the same best QOL indices, same
disease-related damage scores (SLICC/ACR-DI)
and low SLEDAI scores, possibly reflecting a stable
disease overtime. Therefore, these variables had
discriminatory value for comparing survivors and
deceased. 
Similar studies have been carried out in relation
to cancer,13,14 hypertension,15 cardiac insufficien-
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cy,16 acquired immunodeficiency syndrome
(AIDS)17 and the elderly.18 In these studies, the au-
thors clearly reported that patients who yielded
worse scores in health-related QOL questionnaires
had worse prognosis and higher mortality. Effica-
ce et al. (2006)19 reported that in metastatic colo-
rectal cancer cases, a 10-point gain in score of the
social function QOL domain of European Organi-
zation for Research and Treatment of Cancer
(EORTC) QOL Questionnaire – Core -30, would de-
crease the risk of death by 9%. Jacobson et al.
(2003)17 reported that, for patients with acquired
immunodeficiency syndrome (AIDS), in the physi-
cal condition domain of QOL questionnaire speci-
fic for patient with AIDS, each one-point gain from
the baseline score would reduce the chance of
death by 4% and the risks of cytomegalovirus in-
fection and treatment dropout by 2%.16 Using the
SF-36 questionnaire in an investigation on rheu-
matic diseases, Singh et al. (2005)20 reported that
18,464 veterans with rheumatoid arthritis yielded
lower scores in the physical condition QOL doma-
in and that this increased their chance of hospita-
lization and death. 
There have not been any reports in this respect
from SLE patients. However, there are many impor-
tant studies dealing with health-related QOL is-
sues, in which the presence of comorbidities and
damage were important predictors of mortality.21
SF-36 has also been used as a predictor of depres-
sion among such patients.18
In summary, this study presented a health-rela-
ted QOL evaluation of SLE patients and, in parti-
cular, it was found that the emotional aspects of
QOL might provide a means of assessing patients’
prognosis and survival. However, further studies
with longer observation periods and larger num-
bers of patients would be highly recommendable.
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